Several factors — but not older age — increased infection risk with the use of non-TNF biologics following first-line ...

An observational cohort study uses multi-omics profiling to identify distinct biomarkers that could aid in the earlier ...

CHICAGO -- Hitting rheumatoid arthritis (RA) early and hard, with targeted therapies as first-line treatment, appears to ...

A biomarker panel for IPF may identify RA patients at higher risk for ILD, supporting biological overlap between IPF and ...

Interleukin 1 receptor accessory protein (IL1RAP) is a receptor that activates signaling pathways triggered by IL1α/β, IL33 and IL36α/β/γ, which are involved in several autoimmune or inflammatory ...

RA-ILD has worse outcomes than RA and is most likely in those with extra-articular RA manifestations and in those who are older, male, and non-White.

Treatment with TNF-α inhibitors may be safer than IL-6 inhibitors in terms of cardiovascular outcomes when managing patients with RA and T2D.

A study presented at ACR Convergence 2025 suggests that GLP 1 receptor agonists reduce flares and systemic inflammation in ...

Rosnilimab acts as an agonist to stimulate PD-1, killing those cells with high PD-1 expression and pushing others into an ...

In patients with suspected MI with no obstructed coronary arteries, a stratified treatment protocol was superior to standard ...

Researchers assessed treatment patterns and health care resource use among patients with Sjögren disease before vs after diagnosis.

Researchers compared COVID-19 outcomes in rheumatoid arthritis patients treated with biologic vs conventional DMARDs.